Market Research Report
Global Sarcopenia Treatment Market - 2022-2029
|Global Sarcopenia Treatment Market - 2022-2029|
Published: May 7, 2022
Content info: 180 Pages
Delivery time: 2 business days
The global sarcopenia treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).
Sarcopenia is defined by decreased muscular size, relative weakness, a lack of stamina, difficulty climbing stairs, and poor balance. The rate of muscle loss is influenced by exercise level, co-morbidities, nutrition, and others. Sarcopenia can impair one's quality of life and cause disability. It refers to the loss of muscle mass and strength as a natural part of aging. Sarcopenia symptoms include decreased muscle size, weakness, loss of endurance, difficulty climbing stairs, and poor balance.
The global sarcopenia treatment market has been fueled by factors such as an increase in the elderly population and increased acceptance of vitamins and dietary supplements. Furthermore, an increase in sarcopenia cases is expected to drive the growth of the sarcopenia treatment market. Furthermore, an increase in R&D activities for the treatment of sarcopenia is expected to drive the growth of the sarcopenia treatment market.
Increasing vitamin and malnutrition deficiency in underdeveloped countries will drive market growth.
In developing and underdeveloped countries, micronutrient-rich foods are consumed in low proportions, resulting in malnutrition. The most common cause of sarcopenia is malnutrition. Malnutrition is very common in Latin America, Africa, and Southeast Asia due to poor nutritional status. As malnutrition rates rise, so does the prevalence of sarcopenia, creating a high demand for sarcopenia treatment supplements. Vitamin D and B12 deficiency are common among vegetarians and the elderly, and it is the leading cause of sarcopenia. The rising prevalence of vitamin deficiency is expected to demand sarcopenia treatment supplements.
Furthermore, according to data from World Population Prospects(WPP): 1 in 6 people in the world will be over the age of 65 (16%) by 2050, up from 1 in 11 in 2019 (9%), and 1 in 4 people in Europe and Northern America will be 65 or older by 2050. Globally, people aged 65 and up outnumbered children under five in 2018. As a result, the number of people aged 80 and over is expected to treble between 2019 and 2050, from 143 million to 426 million. As a result of the growing aging population and growing interest in preventative healthcare, supplement adoption is on the rise, a major driver in increasing demand for sarcopenia treatment.
Moreover, sarcopenia is a very recurrent disease, but there are no effective treatment options. Sarcopenia is common in the elderly, so many pharmaceutical companies focus on the research and development of drugs to treat sarcopenia. Companies and organizations such as Novartis, Nestle, GSK, the European Working Group on Sarcopenia in Older People (EWGSOP), and the International Osteoporosis Organization are concentrating on research and development well as clinical trials for age-related muscle mass loss. Many pharmaceutical companies have shown positive clinical trial results for drug development. For example, Novartis AG announced in June 2017 the positive results of a 24-week randomized study of Bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. THE MANUFACTURER'S increased R&D activities are expected to fuel the opportunity for sarcopenia treatment market growth.
Low awareness about sarcopenia is likely to hamper market growth.
Sarcopenia is a common illness among orthopedic patients, and it is linked to an increased risk of falling, fractures, mortality, and hospital costs. The sarcopenia therapy market is hampered by a lack of awareness among the senior population, leading to poor diagnosis and treatment.Sarcopenia is also less well-known as a geriatric syndrome than dementia or falls, and it is frequently overlooked in normal aged care. At the same time, treatments for the ailment are still being developed.Furthermore, there are currently no licensed muscle-building drugs to treat sarcopenia in the United States; therefore, non-drug therapies such as exercise, physical therapy, lifestyle, and nutrition change are the sole options. As a result, the absence of effective medicines to treat the illness is a major issue limiting the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic is contemplated to impact the sarcopenia treatment market positively. Patients with sarcopenia are more vulnerable to COVID-19 infection, which causes systemic inflammation and skeletal muscle loss. Furthermore, the need for social isolation during the COVID-19 pandemic has resulted in protein deficiency and decreased daily physical activity in older people, which has accelerated the loss of muscle strength and function. Individuals with COVID-19 are also expected to have 2 or 3 weeks of decreased physical functions, which results in secondary sarcopenia. This increased demand for protein supplements that promote muscle growth and strength. Furthermore, physically isolated people should be encouraged to do daily exercises like the ViviFrail graded exercise set, which is the primary treatment for sarcopenia. As a result, such factors influenced market growth positively in COVID-19.
The protein supplements segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Nutritional supplementation combined with exercise is an effective strategy for weight loss. While all macronutrients can be used for energy production in the human body, only protein serves as a structural and functional compound in all organs and cells, so its demand is expected to rise in the future.
Proteins, particularly those high in leucine, are the most potent branched-chain amino acid for stimulating muscle protein synthesis. Protein supplements aid in preserving muscle mass, strength, and endurance. Anne-Julie Tessier et al. recent .'s evidence supports a higher protein intake recommendation of 1.0-1.2 g/kg/day in healthy older adults; an evenly distributed mealtime protein intake or minimal protein per meal is considered beneficial. As a result, the segment will boost market growth.
North America region holds the largest market share of global sarcopenia treatment market
North America is expected to hold a controlling position in the sarcopenia treatment market due to developed healthcare facilities and technological advancements, which are expected to fuel the market growth during the forecast period. According to the Population Reference Bureau, the number of Americans aged 65 and older is expected to nearly double from 52 million in 2018 to 95 million by 2060, with the 65-and-older age group accounting for 23% of the total population. Sarcopenia affects approximately 45 percent of older adults in the United States, and its prevalence is expected to rise as the population ages. Furthermore, the economic burden of sarcopenia-related healthcare expenditures in the United States is estimated to be USD 18.5 billion per year. Furthermore, the studied market growth in this region is likely to be driven by health awareness and the active presence of major players.
To improve product penetration, the major players in the sarcopenia therapy market have been focusing on new marketing and sales techniques. In addition, the growing preference for online distribution channels has played a significant influence. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Pfizer Inc, GlaxoSmithKline Plc ,Nestle SA, Sanofi SA, Bayer AG, Amway, Cadila Healthcare Ltd, Eli Lilly and Company.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the sarcopenia treatment market globally. For instance, in March 2018, BIOPHYTIS presented Sarconeos (BIO101) results for treating sarcopenia and announced patient enrolment for the SARA-INT international clinical research (ICFSR) at the 8th International Conference on Frailty & Sarcopenia Research.
Also, in July 2019, Nestle has filed a patent for a high-protein blend to prevent muscle loss.
Overview: GlaxoSmithKline PLC is a multinational pharmaceutical company. Pharmaceuticals, Vaccines, and Consumer Healthcare are the three core areas where the company conducts research and development. Tablets, creams/ointments, inhalers, injections, liquids, and sterile items are among the company's product compositions. Its Pharmaceuticals division offers a range of well-known drugs in respiratory, HIV, immuno-inflammation, and oncology. Its Vaccines division provides a vaccination portfolio that can help people defend themselves from various diseases throughout their lifetimes. Pneumococcal illness, meningitis, hepatitis, rotavirus, whooping cough, and influenza are addressed by its vaccinations. Its Consumer Healthcare division blends science and consumer insights to provide everyday healthcare products that consumers trust and that professionals suggest for oral health, pain relief, cold, flu, allergy relief, digestive health, vitamins, minerals, and supplements.
Centrum : Centrum multivitamin and mineral products include up to 26 vital components to address the nutritional needs of children and adults. Centrum also has several specialist formulations that help with energy, immunity, metabolism, eye, heart, bone, and brain health.
Visualize the composition of the global sarcopenia treatment market segmentation by treatment type, Distribution Channel, and region highlighting the key commercial assets and players.
Identify commercial opportunities in global sarcopenia treatment market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global sarcopenia treatment market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global sarcopenia treatment market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
LIST NOT EXHAUSTIVE